Efficacy, Safety, and Immunogenicity of Biosimilar Insulin Aspart Premix SAR341402 Mix 70/30 Compared with Originator Insulin Aspart Mix 70/30 in Adults with Diabetes (GEMELLI M): A Subgroup Analysis by Prior Type of Premix Insulin.

S R AravindKiran P SinghLiliia MogylnytskaAlsu G ZalevskayaBeata Matyjaszek-MatuszekKarin Wernicke-PantenMy-Liên Nguyên-PascalSuzanne PierreBaerbel RotthaeuserDaniel KramerBhaswati Mukherjee

Published in: Diabetes therapy : research, treatment and education of diabetes and related disorders (2022)

EudraCT number 2017-000092-84.

Keyphrases

type diabetes
glycemic control
cardiovascular disease
insulin resistance
clinical trial
metabolic syndrome
weight loss
skeletal muscle
adipose tissue